ATHA
Price
$0.29
Change
-$0.01 (-3.33%)
Updated
Jun 27 closing price
Capitalization
11.52M
50 days until earnings call
ZYME
Price
$12.47
Change
+$0.10 (+0.81%)
Updated
Jun 27 closing price
Capitalization
868.26M
Interact to see
Advertisement

ATHA vs ZYME

Header iconATHA vs ZYME Comparison
Open Charts ATHA vs ZYMEBanner chart's image
Athira Pharma
Price$0.29
Change-$0.01 (-3.33%)
Volume$203.73K
Capitalization11.52M
Zymeworks
Price$12.47
Change+$0.10 (+0.81%)
Volume$2.15M
Capitalization868.26M
ATHA vs ZYME Comparison Chart in %
Loading...
ATHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATHA vs. ZYME commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHA is a Hold and ZYME is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ATHA: $0.29 vs. ZYME: $12.47)
Brand notoriety: ATHA and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATHA: 30% vs. ZYME: 471%
Market capitalization -- ATHA: $11.52M vs. ZYME: $868.26M
ATHA [@Biotechnology] is valued at $11.52M. ZYME’s [@Biotechnology] market capitalization is $868.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATHA’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • ATHA’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than ATHA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATHA’s TA Score shows that 5 TA indicator(s) are bullish while ZYME’s TA Score has 4 bullish TA indicator(s).

  • ATHA’s TA Score: 5 bullish, 5 bearish.
  • ZYME’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ATHA and ZYME are a good buy in the short-term.

Price Growth

ATHA (@Biotechnology) experienced а -2.64% price change this week, while ZYME (@Biotechnology) price change was -0.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ATHA is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZYME($868M) has a higher market cap than ATHA($11.5M). ZYME YTD gains are higher at: -14.822 vs. ATHA (-49.719). ATHA has higher annual earnings (EBITDA): -77.65M vs. ZYME (-110.05M). ZYME has more cash in the bank: 265M vs. ATHA (36.7M). ATHA has less debt than ZYME: ATHA (1.12M) vs ZYME (18.5M). ZYME has higher revenues than ATHA: ZYME (93.4M) vs ATHA (0).
ATHAZYMEATHA / ZYME
Capitalization11.5M868M1%
EBITDA-77.65M-110.05M71%
Gain YTD-49.719-14.822335%
P/E RatioN/AN/A-
Revenue093.4M-
Total Cash36.7M265M14%
Total Debt1.12M18.5M6%
FUNDAMENTALS RATINGS
ZYME: Fundamental Ratings
ZYME
OUTLOOK RATING
1..100
87
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
48
P/E GROWTH RATING
1..100
66
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATHAZYME
RSI
ODDS (%)
Bearish Trend 3 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
77%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
79%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 13 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 13 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
73%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ATHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JFCCX34.040.23
+0.68%
JHancock Fundamental All Cap Core C
CILGX15.550.07
+0.45%
Clarkston Institutional
AMRBX4.670.02
+0.43%
American Growth One B
FASGX29.500.12
+0.41%
Fidelity Asset Manager 70%
PGRKX9.520.02
+0.21%
Principal Global Real Estate Sec R3

ATHA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATHA has been loosely correlated with OGEN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ATHA jumps, then OGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATHA
1D Price
Change %
ATHA100%
-2.64%
OGEN - ATHA
38%
Loosely correlated
+16.05%
MNKD - ATHA
33%
Poorly correlated
-0.27%
SNGX - ATHA
32%
Poorly correlated
-0.73%
ZYME - ATHA
31%
Poorly correlated
+0.81%
PCVX - ATHA
31%
Poorly correlated
-0.91%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with AGIO. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then AGIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
+0.81%
AGIO - ZYME
49%
Loosely correlated
-0.53%
ABCL - ZYME
47%
Loosely correlated
-3.48%
ABEO - ZYME
47%
Loosely correlated
-2.54%
RARE - ZYME
47%
Loosely correlated
-2.43%
IDYA - ZYME
46%
Loosely correlated
-4.13%
More